Navigation Links
Updated Pictures of CEL-SCI Manufacturing Facility Available Online
Date:12/3/2008

VIENNA, Va., Dec. 3 /PRNewswire-FirstCall/ -- In response to numerous shareholder inquiries, CEL-SCI Corporation (NYSE Alternext US: CVM) announced today that it has added updated pictures of it new manufacturing facility to its website. The pictures can be accessed through CEL-SCI's homepage (http://www.cel-sci.com) by clicking on the link "Updated Pictures of Manufacturing Facility" in the special highlights section.

CEL-SCI is developing its cancer product Multikine(R) for approval as a first line indication in head and neck cancer. The manufacturing facility was built to supply the upcoming and FDA cleared Phase III clinical trial, as well as commercial sale, of Multikine as a first line indication in treatment naive head and neck cancer patients. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

CEL-SCI already has two partners who will participate in the Phase III trial: Teva Pharmaceuticals and Orient Europharma of Taiwan. Discussions with other potential partners are ongoing.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% of the patients and to improve the patients' overall survival by 33% at a median of three and a half years following surgery.

CEL-SCI has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. Most recently CEL-SCI announced that its newly discovered rheumatoid arthritis vaccine showed very promising results in animal tests.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. StollerUSA Launches Updated Web site For Growers and Farmers
2. Updated Online Tutorials for DBTSS, Pfam and PDB
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
6. Biopure Launches Updated Website
7. SleepQuest Launches Updated Web Site
8. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
9. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
10. CEL-SCI Takes Delivery of New Manufacturing Facility
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical ... of financing. Healthy investor interest drove significant oversubscription of the original $1.5M target. ... as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
(Date:4/26/2016)... VIENNA and MIAMI ... The prize recognizes the innovation capabilities of ... that will benefit patients and laboratory diagnostics globally. ... , Norma Instruments , an ... products in the field of hematology, announced today ...
(Date:4/26/2016)... ... 26, 2016 , ... The Institute for Venture Science (IVS), ... pre-proposal competition for scientific grants. , The IVS funds promising ideas that challenge ... potential to replace paradigms that have outlived their usefulness. All areas of natural ...
(Date:4/26/2016)... , April 26, 2016 Celsion ... development company, today announced that the first patient ... enrolled in its ongoing global Phase III OPTIMA ... of doxorubicin, in combination with radiofrequency ablation standardized ... treat newly diagnosed patients with primary liver cancer, ...
Breaking Biology Technology:
(Date:3/10/2016)... -- --> --> ... Access Management Market by Component (Provisioning, Directory Services, Password ... Size, by Deployment, by Vertical, and by Region - ... is estimated to grow from USD 7.20 Billion in ... Compound Annual Growth Rate (CAGR) of 12.2% during the ...
(Date:3/8/2016)... 8, 2016   Valencell , the leading ... it has secured $11M in Series D financing. ... new venture fund being launched by UAE-based financial ... existing investors TDF Ventures and WSJ Joshua Fund. ... its triple-digit growth and accelerate its pioneering innovation ...
(Date:3/2/2016)... , March 2, 2016 ... addition of the "Global Biometrics as ... their offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> Research and Markets ( ...
Breaking Biology News(10 mins):